Posters Overview
Glucagon-like peptide-1(GLP-1) mono-, dual-, and triple-receptor agonists, a class of engineered analogs derived from sequence modifications, exert pharmacological effects through activation of GLP-1 receptor or co-activation of receptors for Glucose-dependent insulinotropic polypeptide (GIP), and Glucagon (GCG). These analogs are primarily approved or in development for the management of type 2 diabetes and obesity. Current marketed GLP-1 analogs predominantly incorporate fatty acid chain modifications to enhance pharmacokinetic properties. For such lipid chain modified analogs, comprehensive absorption, distribution, metabolism, and excretion (ADME) studies are essential to elucidate their in vivo behavior.
Complete the form to view and download this poster.
Stay Connected
Keep up with the latest news and insights.